However, because of differentiation of the biological heterogeneity in PCa, currently available biomarkers and indexes cannot precisely estimate the risk in aggressive PCa patients, who may eventually experience BCR, develop castration-resistant prostate cancer, or metastasis. Here, BCR is linked to posterior cortical atrophy.